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Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease with poor survival 
outcomes. Bosentan is an oral endothelin-1 receptor antagonist (ERA) that has been shown in a 
large randomized placebo-controlled trial (BREATHE-1) to be effective at improving exercise 
tolerance in patients with PAH in functional class III and IV. Further studies have been conducted 
showing: benefit in smaller subgroups of PAH, eg, congenital heart disease, efficacy in com-
bination with other PAH therapies, eg, sildenafil, improved long-term survival compared with 
historical controls. More recently, controlled trials of  new ERAs have included patients with milder 
symptoms; those in functional class II. Analysis of the functional class II data is often limited 
by small numbers. These trials have generally shown a similar treatment effect to bosentan, but 
there are no controlled trials directly comparing these new ERAs. The EARLY trial exclusively 
enrolled functional class II patients and assessed hemodynamics at 6 months. Though significant, 
the reduction in pulmonary vascular resistance is merely a surrogate marker for the intended aim 
of delaying disease progression. Significant adverse effects associated with bosentan include 
edema, anemia and transaminase elevation. These may preclude a long duration of treatment. 
Further studies are required to determine optimum treatment strategy in mild disease.
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Introduction to the management of pulmonary 
arterial hypertension
Pulmonary hypertension is a broad term which refers to elevated pressure in the 
pulmonary arterial tree. There are several mechanisms by which this can occur 
and this is reflected in the Venice classification (see Table 1).1 Pulmonary arterial 
hypertension (PAH) is the term used in the presence of changes which directly affect 
the pulmonary vessels, ie, group 1 pulmonary hypertension which is the concern of 
this review. This includes a seemingly diverse group of diseases, but the underlying 
patho-physiology is thought to be similar: vasoconstriction, smooth muscle cell and 
endothelial proliferation, and intravascular thrombosis.2 An updated classification is 
awaited from the expert meeting at Dana Point in 2008, but the make-up of groups 1–5 
will not be significantly altered.
The gold standard diagnostic test is a right heart catheter study and the 
criteria for diagnosis are: mean pulmonary artery pressure (mPAP) greater than 
25 mmHg at rest or 30 mmHg with exercise, pulmonary capillary wedge pressure 
less than or equal to 15 mmHg and a pulmonary vascular resistance (PVR) of greater 
than or equal to 240 dynes/s/cm5.1 The diagnosis of pulmonary hypertension is 
often delayed and requires a thorough assessment to exclude other pathologies and Vascular Health and Risk Management 2009:5 608
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identify the probable cause of pulmonary hypertension. 
Vaso-reactivity challenge is important to identify those 
patients who will benefit from calcium channel blockers.3 
Cardio-pulmonary exercise testing is used at some 
centers and may be helpful to identify those patients with 
exercise-induced pulmonary hypertension.4 It is impor-
tant to exclude chronic thrombo-embolic disease with 
ventilation-perfusion scanning.5 Screening programs using 
echocardiography are recommended for groups at high 
risk of developing PAH: first-degree relatives of patients 
with idiopathic PAH, people with known genetic muta-
tions for PAH, scleroderma, congenital heart disease with 
systemic-to-pulmonary shunts and portal hypertension being 
considered for liver transplantation.3 More information on 
further investigations and determining the type of pulmonary 
hypertension can be found in recognized guidelines.3,5,6
Once a diagnosis of PAH is established there are several 
assessments widely used to monitor progress. The use of 
the World Health Organization (WHO) modified functional 
classification (FC) scale (Table 2) allows for standardized 
grading, which is incorporated into treatment guidelines.3 
The six-minute walk distance (6MWD) is frequently utilized 
in trials of PAH therapy as the primary endpoint. It is an 
appealing measure because of its simplicity and replication 
Table 1 The Venice classification of pulmonary hypertension 2003
Group 1. Pulmonary arterial hypertension
1.1. idiopathic pulmonary arterial hypertension
1.2. Familial pulmonary arterial hypertension
1.3. Pulmonary arterial hypertension associated with:
  1.3.1. Collagen vascular disease, eg, scleroderma, systemic lupus erythematosus, rheumatoid arthritis
  1.3.2. Congenital systemic-to-pulmonary shunts
  1.3.3. Portal hypertension, eg, ethanol induced cirrhosis
  1.3.4. HiV infection
  1.3.5. Drugs and toxins, eg, fenfluramine
  1.3.6.   Other (thyroid disorders, glycogen storage disease, Gaucher’s disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, 
myeloproliferative disorders, splenectomy)
1.4.   Associated with significant venous or capillary involvement
  1.4.1. Pulmonary veno-occlusive disease (PVOD)
  1.4.2. Pulmonary capillary hemangiomatosis (PCH)
1.5. Persistent pulmonary hypertension of the newborn
Group 2. Pulmonary hypertension with left heart disease
2.1. Left sided atrial or ventricular heart disease
2.2. Left sided valvular heart disease
Group 3. Pulmonary hypertension associated with lung disease or hypoxemia
3.1. Chronic obstructive pulmonary disease
3.2. interstitial lung disease
3.3. Sleep-disordered breathing
3.4.   Alveolar hypoventilation disorders
3.5. Chronic exposure to high altitude
3.6. Developmental abnormalities
Group 4. Pulmonary hypertension due to chronic thrombotic, embolic disease, or both
4.1. Thromboembolic obstruction of proximal pulmonary arteries
4.2. Thromboembolic obstruction of distal pulmonary arteries
4.3. Non-thrombotic pulmonary embolism (tumor, parasites or foreign material)
Group 5. Miscellaneous
eg, sarcoidosis, pulmonary Langerhans’-cell histiocytosis, lymphangiomatosis, granulomatous disease, compression of pulmonary vessels 
(adenopathy, tumor or fibrosing mediastinitis)
Adapted with permission from Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;43 Suppl S: 5S–12S. Copyright 
© 2004. elsevier.Vascular Health and Risk Management 2009:5 609
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of the dominant clinical feature of cardio-respiratory 
disease – reduced exercise ability – but also carries prognostic 
significance.7 Additionally oxygen saturations can be mea-
sured at peak exercise, and those patients whose levels fall 
below 90% may benefit from ambulatory oxygen. The Borg 
dyspnea index is a visual analogue score which attempts to 
quantify effort during the 6MWD. General health-related 
questionnaires, such as short form survey 36 and specific ones, 
such as the Camphor questionnaire, are available tools.
Several general measures are recommended for PAH. 
Firstly, where there is an associated cause, eg, sickle cell 
anemia, optimization of this condition is recommended. It is 
noteworthy that pulmonary vasculopathy associated with 
systemic lupus erythematosis and mixed connective tissue 
disease may respond to immunosuppression.8,9 Lifestyle 
advice includes limiting exercise to avoid symptoms, family 
planning advice and advance planning if surgery or anesthesia 
are required.6 Oxygen therapy is appropriate in the presence 
of hypoxemia and should also be considered for those under-
taking air travel as the low cabin pressure may precipitate 
breathlessness. Because of the high risk of intravascular 
thrombosis in the small pulmonary arterioles, anticoagulation 
with warfarin is recommended. For patients in whom right 
heart failure has developed, diuretics are indicated to offload 
excess fluid. Digoxin is often prescribed for its inotropic effect. 
Calcium channel blockers are still used for those patients with 
evidence of a vasodilator response at right heart catheter.6
An understanding of the molecular pathways involved 
has resulted in the development of targeted therapies for 
PAH. There are three main molecules exploited by cur-
rent therapies: prostacyclin, endothelin-1 and nitric oxide.2 
The first therapy developed was the prostacyclin analogue 
epoprostenol which requires a continuous intravenous 
infusion via a central tunneled line. The high maintenance 
requirement and potential complications of this delivery 
means that it is usually reserved for patients in functional 
class IV or who have failed to respond to other therapies.6 
The phosphodiesterase-5 inhibitor sildenafil is licensed 
for PAH in FC I-IV in the USA and FC II-III in Europe. 
Endothelin receptor antagonists (ERAs) including bosentan, 
sitaxentan and ambrisentan are oral therapies licensed for 
use in PAH. As no oral agent has shown superiority there 
remains debate as to which should be used first line. A treat-
ment algorithm for patients with PAH is shown in Figure 1 
to illustrate the place of ERA therapy.6,10
Idiopathic PAH patients make up the majority of study 
participants, with connective tissue disease associated 
pulmonary arterial hypertension (CTD-PAH) a significant 
minority in most trials. Guidance on treatment of specific 
subtypes is therefore limited and recommendations tend 
to follow idiopathic PAH guidelines. The use of ERAs is 
advocated in CTD-PAH as endothelin-1 is felt to play a role 
in the underlying pathogenesis of these diseases.11 Specific 
studies using bosentan in HIV, congenital heart disease and 
pediatric patients have been performed.12–14 Pulmonary veno-
occlusive disease and pulmonary capillary hemangiomatosis 
are rare and pulmonary edema is a significant problem with 
vasodilator therapy.6 Persistent pulmonary hypertension of 
the newborn is managed by neonatalologists. Patients with 
chronic thrombo-embolic disease not amenable to surgery 
can be considered for treatment with specific PAH therapies.15 
Detailed discussion of the differences between various sub-
groups and the formulation of treatment algorithms is beyond 
the scope of this review, and further information can be found 
in other articles.1,6,16
As PAH is a progressive condition it would be an error 
to consider any form of the disease ‘mild’. It is possible 
with screening to detect it at an early stage, when symptoms 
may be mild. The easiest way to define such a group is to 
apply the WHO functional classification and accept those 
in group II as mildly symptomatic. This is far from perfect 
and is heavily based on patients’ subjective reporting and 
physicians’ interpretation. A more objective definition might 
use 6MWD or perhaps the percentage of predicted value, 
Table 2 Functional classification of pulmonary hypertension modified after the NYHA functional classification according to the World 
Health Organization
Class i – Patients with pulmonary hypertension but without resulting limitation of physical activity. Normal physical exertion does not cause undue 
dyspnea or fatigue, chest pain or near syncope.
Class ii – Patients with pulmonary hypertension resulting in slight limitation of physical activity.   They are comfortable at rest. Ordinary physical activity 
causes undue dyspnea or fatigue, chest pain or near syncope.
Class iii – Patients with pulmonary hypertension resulting in marked limitation of physical activity.   They are comfortable at rest. Less than ordinary 
physical activity causes undue dyspnea or fatigue, chest pain or near syncope.
Class iV – Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms.   These patients manifest signs 
of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.Vascular Health and Risk Management 2009:5 610
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possibly with additional Borg dyspnea scores or quality 
of life measures. There are many potential confounders, 
eg, chronic adaptation, symptom exacerbation by co-morbid 
conditions like lung fibrosis and anemia. It is difficult to see 
how these could be fully accounted for and so any system, 
however complicated, is likely to remain flawed. Because 
of the high mortality in untreated cases there are much data 
on prognostic implications of various parameters, eg, right 
atrial pressure (RAP), cardiac index (CI), but these do not 
correlate with symptoms. Therapies are not licensed subject 
to hemodynamic parameters or 6MWD and consequently 
functional classification is the major determinant of initial 
therapy in PAH.
Bosentan has been licensed for the treatment of FC III/IV 
PAH since 2002 in North America and Europe. At that time 
treatment was either calcium channel blockers (for those with 
a positive vasodilator response) or intravenous prostanoids. 
Bosentan was therefore a practical first-line option for many 
Diagnosis  of  PAH  at  right  heart  catheter 
Supportive  therapy:  warfarin,  diuretics,  
digoxin,  oxygen,  lifestyle  advice
Vasoreactivity  test  positive: 
Calcium  channel  blockers
Vasoreactivity  test  negative 
Mild/FC  II 
PDE-5  inhibitor 
or ERA 




Prostanoids  iv 
2nd line 
2nd line  2nd line 
ERA   or 
PDE-5  inhibitor 
PDE-5  inhibitor 
or  ERA 




Oral  combination 
therapy 
Combination  iv and    
oral  therapy 
Atrial  septostomy  
Lung  transplant 
Add  inhaled  iloprost 
Prostanoids  iv 
Trials
Sustained response and FC  No
Yes 
Continue 
Figure 1 Outline treatment algorithm for pulmonary arterial hypertension (PAH) at a specialist center.
Abbreviations: eRA, endothelin-1 receptor antagonist; FC, functional classification.Vascular Health and Risk Management 2009:5 611
Bosentan for PAH in the mildly symptomatic patient Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
patients, and though other oral agents are now available it is 
still a mainstay of PAH therapy either as monotherapy or, 
increasingly, as part of combination therapy.
Overview of pharmacology 
of bosentan in pulmonary arterial 
hypertension treatment
The mechanism of action of bosentan is competitive 
inhibition of endothelin-1 receptors.17 Endothelin-1 
is a potent vasoconstrictor, which also mediates cell 
proliferation, fibrosis and inflammation. It is mainly synthe-
sized in endothelial cells and acts locally in autocrine and 
paracrine fashion.18 Two subtypes of endothelin-1 receptor 
exist; when found on vascular smooth muscle cells they 
mediate vasoconstriction. Endothelin receptor subtype A 
(ETA) is predominantly found in smooth muscle and also on 
fibroblasts, whereas receptor subtype B (ETB) is expressed 
on smooth muscle and endothelial cells.19 Endothelial ETB 
activation mediates clearance of endothelin-1 and vasodi-
latation by nitric oxide and prostacyclin release.18 Because 
of these effects ETB activation is theoretically desirable in 
PAH. Selective agents with relative ETA:ETB affinity of 
greater than 100:1 have been developed, eg, sitaxentan, rela-
tive affinity 6500:1, which have also been shown to reduce 
endothelin-1 levels.19 Bosentan exhibits a relative ETA:ETB 
affinity of 20:1 by in vitro assays and is therefore classed 
as a dual ERA.20 Although ETA selectivity is attractive, 
these selective agents have not been shown to be superior 
to bosentan in clinical trials.
Bosentan is an orally active nonpeptide compound with 
the chemical formula C27H29N5O6S-H2O.17 It is usually 
started at a dose of 62.5 mg twice daily and uptitrated 
after 4 weeks to 125 mg twice daily. Bosentan reaches 
peak plasma concentration three to 5 hours after consump-
tion with an absolute bioavailability of 50% that is not 
affected by food.20 Bosentan is 98% bound to albumin 
with a volume of distribution of 30 L and a terminal half-
life of 5.4 hours.20 Steady-state plasma concentrations are 
achieved in 5 days with a multiple dose regimen.20 The 
pharmacokinetics of bosentan are dose proportional up 
to 500 mg/day. Adult patients with PAH have a 2-fold 
increased exposure compared with pediatric patients and 
healthy subjects.20 Severe renal impairment (creatinine 
clearance 15 to 30 mL/min) and mild hepatic impairment 
(Child-Pugh class A) do not have clinically relevant 
effects, but moderate to severe hepatic impairment are 
relative contraindications.20
Metabolism of bosentan in the liver occurs by the 
cytochrome p450 enzymes CYP2C9 and CYP3A4, with 
excretion of metabolites in the bile. One of the three metabo-
lites identified, Ro 48-5033, may be pharmacologically 
active.20 Bosentan is an inducer of the CYP2C9 and CYP3A4 
enzymes which may explain the increased clearance and 
reduced plasma levels of bosentan seen at steady-state.20 
This induction affects the plasma levels of other compounds 
metabolized by these enzymes: ciclosporin, glibenclamide, 
simvastatin and warfarin. Specifically, simvastatin levels 
may be reduced by 50%; warfarin concentrations are reduced 
but no relevant changes in INR have been experienced.20 
Glibenclamide and bosentan concentrations are both reduced 
when co-administered, and here is also an increased risk of 
transaminase elevation.20 Concomitant ciclosporin use results 
in a reduced ciclosporin concentration and a tripled bosentan 
steady-state concentration via CYP3A4. The use of ciclo-
sporin and glibenclamide with bosentan is contraindicated. 
Inhibitors of CYP2C9 (fluconazole, amiodarone) and 
CYP3A4 (ketoconazole, itraconazole) can be expected to 
increase bosentan concentration.20 Another important inter-
action occurs with oral contraceptive agents: concomitant 
bosentan reduced norethisterone and ethinyl estradiol levels 
in a pharmacokinetic study and therefore hormonal contra-
ception cannot be relied on.21
Bosentan and Ro 48-5033 have been shown to be 
substrates of the human organic anion transporting 
polypeptides OATP1B1 and OATP1B3.22 Ciclosporin A 
and rifampicin have been shown to inhibit these hepatic 
uptake transporter molecules which may explain increases in 
bosentan levels seen with co-administration.22 The increase 
in bosentan trough levels seen initially with rifampicin 
turns into a decrease in steady-state conditions probably 
due to p450 enzyme induction.23 Ritonavir also inhibits 
OATP-mediated uptake and pharmacological studies have 
shown increased bosentan levels when co-administered with 
lopinavir and ritonavir.24 There was also a small reduction 
in lopinavir and ritonavir and concomitant use of bosentan 
and anti-retrovirals requires close monitoring. Both enzyme 
induction and OATP inhibition may be important in the 
interaction with sildenafil, another oral therapy used in PAH. 
In healthy subjects, co-administration of bosentan 125 mg 
twice daily and sildenafil 80 mg 3 times daily resulted in a 
50% rise in bosentan levels and fall in sildenafil by nearly 
two thirds.25 Tadalafil is a phosphodiesterase-5 inhibitor 
currently in phase III trials for PAH. It is metabolized by 
CYP3A4 and healthy volunteer studies showed similar 
results, with reduction in tadalafil levels and increased Vascular Health and Risk Management 2009:5 612
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bosentan exposure when co-administered.26 This may be 
clinically important but long-term data are awaited from 
combination studies in PAH.
Efficacy studies, including 
comparative studies
Bosentan has been studied in several clinical PAH trials with 
generally positive results. The first human study of bosentan 
treatment used an intravenous preparation which successfully 
reduced mPAP and PVR.27 Unfortunately, it also provoked 
a drop in systemic arterial pressure and vascular resistance 
and subsequently an oral preparation has been favored.27 
After the benefit of oral bosentan in PAH was established 
in a randomized trial, subsequent papers have attempted to 
answer several outstanding questions. These include: long-
term effect on survival, efficacy in subgroups of PAH and 
chronic thromboembolic disease, safety and benefit when 
used in combination with other PAH therapies, and the 
value in milder disease. A review of the relevant studies with 
consideration of these questions follows and a summary of 
bosentan trials is shown in Table 3.12–15,28–36
In 2001, a small double-blind, randomized, placebo-
controlled trial (study 351) was published. Trial subjects were 
all in FC III with a 6MWD of 150 to 500 m and had either 
idiopathic PAH or PAH associated with scleroderma. After 
12 weeks improvement was seen in the primary endpoint, 
the 6MWD, of 70 m and 76 m compared with baseline and 
placebo respectively.28 Repeated hemodynamic studies per-
formed showed marked improvement in mPAP, PVR, RAP 
and CI compared with placebo as well.28 Although all cases 
started in FC III, by 12 weeks nine of the bosentan treatment 
arm were in FC II.28 The open-label extension showed the 
effect on 6MWD to be maintained at 6 months and after a 
year of therapy a significant number (41.4%) of patients had 
improved functional class.37 To confirm the positive results of 
study 351 a multi-center, double-blind, randomized trial was 
undertaken. BREATHE-1 compared bosentan 125 mg and 
250 mg twice daily with placebo over 16 weeks. 213 patients 
in WHO FC III and IV owing to idiopathic PAH or CTD-PAH 
with 6MWD of 150 to 450 m were enrolled. The observed 
treatment effect of bosentan on 6MWD was 35 m for the 
lower dose, licensed dose.29 Other observations made were: 
improved FC in 42%, now and reduced Borg dyspnea index 
and prolonged time to clinical worsening (TTCW) compared 
with placebo.29 One-year and 2-year survival data from the 
bosentan trial patients with idiopathic PAH (96% and 89%) 
compare favorably with National Institutes of Health registry 
predicted survival rates (69% and 57%).38 These are not truly 
Table 3 PAH studies reporting effect of bosentan
First author Name Year N= Groups Comparator Design Effect vs comparator P-value
Channick28 Study 351 2001 32 iPAH; SSc Placebo DB R 6MwD +76 m p  0.05
Rubin29 BReATHe-1 2002 213 iPAH; CTD Placebo DB R 6MwD +35 m (250 mg) p  0.01
Barst13 BReATHe-3 2003 19 Baseline OL mPAP −8 mmHg
PVR –300 dynes/s/cm5
Humbert30 BReATHe-2 2004 33 iPAH; CTD Placebo R PVR −188 dynes/s/cm5 ns
Sitbon12 BReATHe-4 2004 16 HiV Baseline OL 6MwD +91 m p  0.001
wilkins31 SeRAPH 2005 26 iPAH; CTD Sildenafil R 6MwD −16 m ns
Barst32 STRiDe-2 2006 185 iPAH; CTD; CHD Sitaxentan OL R 6MwD +1.5 m ns
Galiè14 BReATHe-5 2006 54 CHD Placebo DB R PVRi −472 dynes/s/cm5 p  0.05
6MwD +53 m p  0.01
Mathai33 2006 25 iPAH; SSc Baseline OL 6MwD +52 m ns
Denton34 TRUST 2007 53 CTD Baseline OL 12 patients improved FC
Akagi35 2008 8 iPAH Baseline OL mPAP −13 mmHg p  0.05
Galiè36 EARLY 2008 185 iPAH; CHD; CTD; HiV Placebo DB R 6MwD +19 m ns
PVR −197 dynes/s/cm5 p  0.0001
Jaïs15 BeNeFiT 2008 99 CTePH Placebo DB R PVR −193 dynes/s/cm5 p  0.0001
6MwD +2 m ns
Abbreviations: iPAH, idiopathic pulmonary artery hypertension; SSc, scleroderma-associated pulmonary arterial hypertension; CTD, connective tissue disease associated 
pulmonary artery hypertension; HIV, human immunodeficiency virus associated pulmonary artery hypertension; CHD, congenital heart disease associated pulmonary artery 
hypertension; CTePH, chronic thromboembolic pulmonary hypertension; DB, double blinded; R, randomized; OL, open label, 6MwD, six-minute walk distance; mPAP, mean 
pulmonary artery pressure; PVR, pulmonary vascular resistance; FC, functional class.Vascular Health and Risk Management 2009:5 613
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comparable data, but are important because trials in PAH have 
been unable to show survival benefit in the short controlled 
phases (a frequent criticism).
The majority of study participants in BREATHE-1 were 
idiopathic PAH patients. Subgroup analysis of BREATHE-1 by 
diagnosis suggests a difference in response. Bosentan improved 
6WMD in idiopathic PAH, whereas it prevented deteriora-
tion in CTD-PAH: a 3 m improvement was seen compared 
to a 40 m decline in placebo-treated CTD-PAH patients.29 
Combined analysis of the CTD-PAH patients in study 351 and 
BREATHE-1 suggests a trend favoring bosentan with a 22 m 
improvement in 6MWD.39 This was despite less favorable 
baseline 6MWD and PVR. Survival estimates of 86% and 73% 
at 1 and 2 years, respectively, although better than historical 
data, were not as good as for idiopathic PAH.39 The TRUST 
study sought to assess survival and quality of life in CTD-PAH 
patients. At 48 weeks, the survival was 92% with absence of 
clinical worsening in 68% by Kaplan-Meier estimation.34 The 
broader implication of these data is that benefit seen in one type 
of PAH may not be manifest in another. The BREATHE-4 study 
demonstrated benefit in 16 patients with HIV associated PAH. 
Sixteen weeks of bosentan therapy improved 6MWD to 424 m 
from 333 m at baseline, with hemodynamic improvement and 
13 patients attaining FC II status.12 A placebo-controlled study 
(BREATHE-5) looked at the effects of bosentan in 52 subjects 
with Eisenmenger syndrome with an added safety endpoint of 
systemic oxygen saturation. 6MWD, mPAP and PVR were 
significantly improved with only a 1% drop in oxygen satura-
tions.14 Data from the open-label extension reported an overall 
improvement in 6MWD at 24 weeks with a drop of only 0.5% 
in systemic arterial saturations.40 A multi-center trial of bosentan 
in patients with inoperable chronic thromboembolic pulmonary 
hypertension showed hemodynamic improvement but not ben-
efit in exercise capacity.15
As PAH is a progressive condition it seems reasonable to 
suppose that early treatment can prevent clinical deterioration 
in mildly symptomatic patients. Most trials have reported 
subjects improving from FC III to II before the open-label 
extension. Therefore many patients in FC II have received 
treatment, albeit they had to deteriorate to FC III status first. 
Unfortunately this reflects what happens to many FC II 
patients in practice. The combined open-label extension 
studies do not contain enough evidence to justify treating 
those in FC II. Although patients in FC II have higher mor-
tality and event rates than healthy subjects, these rates are 
lower than seen in FC III and IV patients. An event-driven 
outcome would therefore require a longer placebo-controlled 
period than was ethically acceptable for the early PAH trials. 
BREATHE-1 reported a diminished 6MWD treatment effect 
in patients with more favorable hemodynamics: mPAP 
of  50 mmHg and CI  2.3 L/min/m2.29 The limited effect 
on 6MWD with sitaxentan in STRIDE-1 raised concerns of 
a ceiling effect in 6MWD improvement, as no upper limit of 
6MWD was specified.41 Trials with disappointing results may 
point to the inclusion of those with milder PAH as a poten-
tial confounder, but several trials with a minority of FC II 
patients have posted significant results (see Table 4).32,36,42–50 
Enough FC I and II patients were treated in the SUPER-1 and 
ARIES trials to show effect on 6MWD in these subgroups.42,44 
Long-term follow-up data from patients treated with the ERA 
ambrisentan show improved 6MWD at 2 years, relative to 
baseline, and estimated survival of 95%.51
The EARLY trial remains the only PAH trial designed 
specifically for FC II patients. It was prospective, double-
blinded, randomized and placebo-controlled. Patients with 
idiopathic, familial, HIV, anorexigen, connective tissue 
disease and congenital heart disease (with some restrictions) 
associated PAH were recruited.36 Rather than fixing an 
absolute upper limit for the baseline 6MWD a value of 
less than 80% predicted or 500 m with a Borg score  2 
and a PVR  320 dynes/s/cm5 were specified. Co-primary 
endpoints of change in PVR and 6MWD at 6 months were 
used. Secondary endpoints included TTCW and change 
from baseline to 6 months in: WHO FC, Borg score, RAP, 
mPAP, CI and mixed venous oxygen saturation (mVO2). 
Definitions of TTCW vary between trials. EARLY used 
death, hospitalization due to PAH complications and symp-
tomatic progression (new or worsening right heart failure 
or a 10% reduction in 6MWD from baseline assessed twice 
more than 2 weeks apart or 5% reduction in 6MWD from 
baseline assessed more than 2 weeks apart with an increase 
in Borg score of at least 2 points). Using this definition the 
clinical worsening event rate was 14% in the placebo group 
over 6 months.36
Of the 476 patients screened 139 were not felt to be in 
functional class II and 76 met exclusion criteria.36 Due to 
trial rules only 81 patients taking bosentan and 82 assigned 
placebo completed the study. Mean 6MWD data suggested 
a trend towards improvement with bosentan: +11.2 m 
versus −7.9 m for placebo.36 Analysis of PVR values using 
the Wilcoxon rank-sum test showed a significant decrease 
in PVR for the bosentan group (83.2% versus placebo 
107.5%).36 Other hemodynamic variables that showed 
improvement were mPAP, CI and mVO2.36 TTCW was 
delayed with bosentan therapy (p  0.02) compared with 
placebo with a hazard ratio of 0.23.36 Twelve patients taking Vascular Health and Risk Management 2009:5 614
Valerio and Coghlan Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
placebo progressed to FC III compared with only 3 patients 
on bosentan (p  0.05). N-terminal-pro-BNP levels were 
only assessed in certain pre-specified centers; the treatment 
effect was −471 ng/L (p  0.0005) comparing bosentan with 
placebo.36 Overall the results were therefore positive, even 
if some of the selection criteria were unusual.
With specific therapies for PAH acting on three different 
pathways and their efficacy as monotherapy proven, a 
logical step forward has been to look at combining agents. 
In BREATHE-2, 33 patients starting intravenous epoprostenol 
were randomized to either additional placebo or bosentan. 
Assessment at 16 weeks showed 6MWD and functional 
class improvement in both groups with a trend towards better 
hemodynamics in the bosentan-treated patients.30 A small 
study conducted in Japan also showed improvement with 
the addition of bosentan to epoprostenol in idiopathic PAH. 
Eight patients on stable doses of epoprostenol (average 
100 ng/kg/min) had continuous hemodynamic monitoring 
for 2 days during initiation with 62.5 mg bosentan twice 
daily.35 Even while reducing epoprostenol to maintain SvO2 
at baseline value, systolic pulmonary artery pressure and PVR 
fell; these changes were maintained in six of the patients at 
1 year.35
Several investigators have looked at the combination 
of bosentan and sildenafil. In an observational cohort 
of 9 patients with idiopathic PAH adjunctive therapy was 
deemed necessary after several months due to deterioration.52 
Initial response to bosentan was significant (+57 m) to 
an average of 403 m, but this fell to just 277 m at the 
time of adding sildenafil between 6 and 16 months later. 
The resulting increase in 6MWD (+122 m) was sustained 
for 6 months.52 In a group including 13 idiopathic PAH 
and twelve scleroderma-associated PAH patients started 
on bosentan monotherapy, sildenafil was offered instead of 
intravenous therapy, after clinical deterioration. Improvement 
in FC and 6MWD was only seen in the idiopathic PAH group 
however.33 Sildenafil received a license for use in PAH while 
the EARLY trial was ongoing. Because of this development 
an amendment was made to the study protocol allowing 
concomitant sildenafil use; provided it was started more than 
one month before enrolment and the dose remained steady 
during the trial. The FC status of these 28 patients before 
commencing sildenafil is not known. The reduction in PVR 
in this group was similar to that seen in the main analysis but 
the confidence interval ranged from −44% to 13% because 
of the small numbers.36 A trend towards reduction in 6MWD 
was also seen in this subgroup.36
The effects of bosentan have also been compared with 
other specific therapies for PAH. The SERAPH investiga-
tors randomized 26 patients with PAH in FC III to either 
standard regimen bosentan or sildenafil (50 mg twice daily 
for 4 weeks, then 50 mg 3 times daily).31 At 16 weeks there 
were no significant differences in effect between the two 
drugs: bosentan improved 6MWD by 59 m compared with 
75 m in the sildenafil group.31 Both therapies improved CI, 
but only sildenafil reduced plasma BNP levels.31 A survival 
comparison with a historical cohort of 346 IPAH patients 
treated with epoprostenol favored bosentan. One hundred 
Table 4 PAH studies including (more than 10) patients in FC ii
Author/study Year Treatment Design Endpoint Effect No. FC II Treat FC II 
analysis
Galiè SUPeR-142 2005 sildenafil DB R P 6MwD +42 m p  0.001 108 of 278 75* +40 m
Galiè43 2005 ambrisentan DB R P 6MwD +36 m p  0.0001 23 of 64 17 +58 m
Galiè EARLY36 2008 bosentan DB R P PVR −197 p  0.0001 185 of 185 93 n/a
6MwD +19 m ns n/a
Galiè ARieS44 2008 ambrisentan DB R P 6MwD +43 m 165 of 383 113* 36–55 m
Simonneau UT1545 2002 trepostinil DB R P 6MwD +10 m 53 of 470 25 No
Galiè ALPHABeT46 2002 beraprost DB R P 6MwD +15 m 64 of 130 31 No
Barst47 2003 beraprost DB R P VO2 max p  0.002 61 of 116 33 No
Barst STRiDe-148 2003 sitaxentan DB R P VO2 max +1.1 59 of 178 37 No
Sastry49 2004 sildenafil DB X P Treadmill test +211s p  0.0001 18 of 22 18 No
Barst STRiDe-232 2006 sitaxentan DB R P 6MwD +28 m p  0.05 92 of 185 47 No
bosentan 6MwD +29 m p  0.05 22 No
Simonneau PACeS50 2008 sildenafil DB R P 6MwD +29 m 71 of 267 35* No
Notes: Treat column refers to the number of patients enrolled in each trial in FC i or ii and assigned to treatment arm. *includes FC i patients.
Abbreviations: DB, double blind; R, randomized; P, placebo-controlled; X, crossover; 6MwD, six-minute walk distance; PVR, pulmonary vascular resistance; FC, functional class.Vascular Health and Risk Management 2009:5 615
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and thirty-nine patients in FC III at commencement of 
bosentan had a survival of 97% and 91% at 1 and 2 years 
compared with 91% and 84% with epoprostenol.53 The 
STRIDE-2 trial included an open-label bosentan arm in 
addition to the placebo and sitaxentan treatment arms. After 
18 weeks, sitaxentan 100 mg and bosentan both increased 
6MWD; the difference in treatment effect was less than 
two metres.32 Sitaxentan also improved functional class but 
neither treatment delayed time to clinical worsening.32 The 
extension study converted all patients to 100 mg dose and 
followed up for 1 year. No difference was seen in 6MWD 
or change in functional class.54 For the CTD-PAH subgroup; 
the difference in TTCW reached significance favoring 
sitaxentan (hazard ratio 0.20).55 There are no data compar-
ing bosentan and ambrisentan but efficacy data from trials 
with the three available ERAs do not suggest superiority 
of any one agent.
Safety and tolerability
The ERA class of drugs are associated with many side effects 
and even though significant safety problems are rare, there 
are many cautions necessary for their use. As discussed 
earlier, the pharmacology of bosentan and ERAs can induce 
hepatic enzymes making hormonal contraception unreliable. 
Of course they are contraindicated in pregnancy as well 
due to teratogenicity. Breast-feeding is not recommended 
either because it is unknown whether ERAs pass into breast 
milk. The safety of bosentan use in children with PAH 
has been explored in an open label study which confirmed 
safe dose reduction in the pediatric population. Concurrent 
use of ciclosporin A with any ERA is contraindicated and 
glibenclamide with bosentan due to drug-drug interactions. 
Experience with bosentan in HIV associated PAH is limited 
and interaction with anti-retroviral drugs requires careful 
monitoring for the same reasons.12 Clinical studies report 
very few patients stopping bosentan, but many experiencing 
adverse effects.
The principal problem with bosentan is hepatotoxicity 
initially manifest as elevated levels of alanine amino-
transferase and aspartate aminotransferase. The bosentan 
information insert quotes an incidence of 11% for elevation 
of these liver enzymes to levels more than 3 times the 
upper limit of normal (ULN).56 These changes are dose-
dependent; in BREATHE-1 there was a 14% incidence 
of hepatic enzyme elevation in the 250 mg twice daily 
group compared with 4% in the 125 mg arm and 3% in the 
placebo arm.29 Levels above 8 times the ULN occurred 
in 2 patients on the 125 mg twice daily and 5 patients taking 
250 mg twice daily.29 In BREATHE-5, 2 of the 37 patients 
developed elevated transaminases; this led to discontinua-
tion in one case.14 In TRUST, 17% of CTD-PAH patients 
developed elevated liver enzymes, requiring discontinuation 
of bosentan in three.34 Postmarketing surveillance reports 
led to a strengthening of the warning on monthly liver 
enzyme monitoring. This includes one case of biopsy con-
firmed cirrhosis in a patient taking bosentan.57 Although 
the patient was suffering from an intravenous catheter 
related infection and subsequently recovered; a contribution 
of bosentan to the liver damage could not be excluded.57 
A more recent case of hepatotoxicity that developed with 
the addition of methotrexate, resolved after bosentan 
was stopped and did not recur with reintroduction of 
methotrexate.58 Currently, product guidance recommends 
stopping bosentan if levels are more than 5 times ULN, 
and re-introduction can only be considered if levels were 
less than 8 times ULN. For levels between 3 and 5 times 
ULN dose reduction may be adequate, but fortnightly 
monitoring is recommended.56 Although lasting damage 
has occurred rarely, hepatic enzyme elevation is the most 
frequently cited reason for bosentan discontinuation. The 
reported incidence of elevated transaminases is lower with 
sitaxentan (7%) and ambrisentan (1%) therapy. It should 
be noted that the incidence in the placebo groups in these 
trials is also lower.19
Hemoglobin levels fall by approximately 0.9 g/dL with 
bosentan therapy, predominantly in the first few weeks of 
therapy with stabilization beyond 12 weeks.20 A decrease 
of 1 g/dL was seen in 68% of patients treated with 
bosentan compared with 29% on placebo.56 Three patients 
in study 351 had significant falls in hemoglobin recorded; 
levels did not drop below 10.4 g/dL though.28 One patient 
in BREATHE-5 developed a significant anemia with a 
hemoglobin of 10 g/dL.14,40 The effect of chronic oral 
therapy on blood pressure does not seem to be dramatic; 
in contrast to the intravenous preparation. Mean systemic 
arterial pressure fell by 3 mmHg in BREATHE-1 and 
4 mmHg in BREATHE-5.14,29 A safety endpoint was included 
in BREATHE-5 because of concerns that saturations may 
be reduced by bosentan. There was a nonsignificant, small 
reduction in mixed venous saturations in the bosentan group 
with no adverse events reported as a result.14
When bosentan was trialled as therapy for chronic 
heart failure it provoked increased peripheral edema 
within weeks.18 This effect has been documented in PAH 
with an incidence of 10% in study 351 and many patients 
anecdotally requiring diuretics or hospital treatment.28 Vascular Health and Risk Management 2009:5 616
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Rates in other PAH trials are higher, eg, BREATHE-2 27%, 
BREATHE-5 19% and TRUST 17%.14,30,34 The mechanism 
of edema is not entirely clear; in some patients it may be 
sequelae of worsening right heart failure (and some trials 
have considered it so). It may be the result of vasodilata-
tion caused by ERAs, or from effects upon renal tubular 
function.18 In the open-label extension of study 351, a large 
number of adverse symptoms were reported: headache, 
dizziness, cough, dyspnea, syncope, flushing, respiratory 
tract infection, chest pain, palpitation, fatigue, arthralgia, 
dyspepsia, epistaxis and nausea.28 Many of these might be 
attributable to progression of PAH and were not seen with 
significantly greater frequency in the bosentan groups com-
pared with placebo in BREATHE-1.29 Headache, dizziness, 
palpitations and chest pain were seen more frequently in the 
bosentan group in BREATHE-5.14 Diarrhea, exacerbated 
dyspnea and nausea were reported in more than 10% of 
TRUST participants.34 These differences in reported side 
effects may reflect the different study populations.
From the limited amount of data available, most of which 
is not placebo-controlled, it seems combination therapy is 
well tolerated. In one report of bosentan and sildenafil com-
bination no greater number of liver enzyme elevations were 
seen compared with bosentan monotherapy.10 In another trial 
several patients had to stop sildenafil for severe dyspepsia 
(mostly CTD-PAH). Two patients developed LFT abnormali-
ties after addition of sildenafil – one resolved with discontinu-
ation of sildenafil, the other with reduction of bosentan. One 
patient developed intractable headaches which required dis-
continuation of sildenafil. In BREATHE-2 peripheral edema 
was significantly more common in the bosentan/epoprostenol 
group, although liver enzyme elevation was seen more often 
in the placebo/epoprostenol group.30
Obviously, when using a drug in situations where there 
may be less positive clinical effect, safety must come 
under closer scrutiny to ensure that the risk-benefit ratio 
is still favorable. The commonest adverse events in the 
bosentan group in the EARLY trial were nasopharyngitis 
and elevated liver enzymes.36 Twelve patients on bosentan 
developed transaminase levels over 3 times ULN, 10 within 
20 weeks. In all cases transaminase levels returned towards 
baseline levels with appropriate management (at least 
6 discontinued altogether). In the open-label extension seven 
serious adverse events occurred: cardiac failure and anemia, 
progression of PAH, abnormal liver enzymes (n = 3), 1 death 
after seizures probably caused by vasculitis reactivation, 
and an episode of toxic epidermal necrolysis and acute 
hepatitis.36 Postmarketing surveillance reports have flagged 
hypersensitivity, rash, thrombocytopenia, jaundice, anemia 
requiring transfusion and hepatic cirrhosis/failure as seri-
ous adverse events. These potentially grave consequences 
bear thought when considering therapy in those with mild 
symptoms.
Patient-focused outcomes such  
as quality of life
Several different scores can be used to quantify the patient’s 
perception of improvement in PAH. The Borg dyspnea 
index or score is the most widely used patient-reported 
measure in PAH trials; a fall in the score suggests less 
exertional breathlessness. This was seen in study 351 and 
BREATHE-1 with a net treatment effect of −0.6 (CI −1.2 
to −0.1) in the latter.28,29 BREATHE-4 found bosentan 
improved Borg score in HIV associated PAH (1.5 vs 3.4 at 
baseline, p  0.02).12 Perhaps it should have been expected 
that there was no change in Borg score was seen in the 
EARLY trial.36 BREATHE-2 used a dyspnea-fatigue index 
which did not change with the addition of bosentan.30
PAH trials have not consistently used any one 
symptom scoring system. Although the camphor score was 
specifically designed for PAH the different aims of trials 
means it is often not suited for this purpose. Quality of 
life assessed by the EQ-5D visual analog scale improved 
in BREATHE-4 (p  0.001), as did 6 of the 8 items 
in the SF-36 health survey form: physical functioning, 
role-physical, general health perception, vitality, social 
functioning, mental health.12 The TRUST study analyzed 
a broader set of items looking for additional benefits in 
connective tissue disease patients. There were minimal 
improvements at 48 weeks in SF-36 scores; more patients 
felt they had improved than deteriorated on the health 
transition item (mean −0.83, 95% confidence intervals 
−1.27 to −0.39).34 The health assessment questionnaire and 
visual analogue scores used tended to increase suggesting 
a lack of perceived benefit.34 In EARLY the SF-36 health 
questionnaire scores suggested that 57% of bosentan 
patients and 38% of placebo patients felt their condition 
had improved (p  0.05).36 Breakdown of domains did 
not show significance for any individual part, the most 
marked trend was for general health perceptions followed 
by role-physical and mental health and vitality.
Conclusions, place in therapy
The progressive natural history of PAH gives us a clear 
rationale for treating the disease early. However, the Vascular Health and Risk Management 2009:5 617
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criteria we use to decide who to treat and how we treat 
them are still open to debate. The combined complexities 
of ethics and study design for this patient group mean 
the optimal trial endpoints are not clear. The EARLY 
trial shows that unless they are treated we can expect 
patients in FC II to progress to a more symptomatic state. 
Recent meta-analysis of PAH trials has demonstrated 
improved survival with targeted therapy; resulting in 
a number needed to treat of 20 to prevent one death at 
1 year.59 While survival is perhaps the dominant concern 
in patients with more severe disease, ideally those at the 
milder end of the spectrum would not progress that far. 
Those therapies which provide mortality benefit in severe 
disease may not delay progression in the earlier stages as 
effectively as other agents. Advocates of targets in PAH 
therapy would include FC II status as a clear goal. Thus, 
many PAH patients who are in FC II are treated, if only 
because they have shown clinical evidence of deterioration 
previously. Waiting for such evidence before commenc-
ing therapy is not a logical approach. The EARLY trial 
provides clear evidence for treating the FC II patient; 
this is supported by sub-group data from other trials, eg, 
ARIES.36,44
Bosentan has been shown to be effective at improv-
ing exercise tolerance in PAH patients in FC III and IV in 
randomized controlled trials. Of the currently available oral 
therapies for PAH there is more long-term data relating to 
bosentan use. The existence of small studies which have 
addressed specific problems and subgroups provides reas-
surance when confronted with the more unusual cases. In the 
absence of comparative data showing superiority of any oral 
therapy in terms of clinical effect, prescribing decisions may 
be based on other factors. Given the likelihood that a treat-
ment for FC II patients may be needed for several years the 
ideal drug would be one without significant side effects or 
drug interactions. No oral therapy is free of adverse effects 
but bosentan has perhaps a worse side effect profile than 
the other ERAs and phosphodiesterase-5 inhibitors. Long-
term and post-marketing data are awaited to see if the lower 
incidence of adverse events reported in trials of other agents 
persists. In conclusion, bosentan seems to offer benefit to 
those patients with PAH in FC II, but the relatively high 
incidence of adverse events may be prohibitive for some 
patients and clinicians.
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